Management of infections caused by resistant organisms is both challenging and rapidly evolving. Some of the treatment options mentioned in this review may not be based on high quality evidence as these options are not supported by well conducted RCTs. Newer agents like plazomicin, cefiderocol, meropenem-vaborbactam and imipenem-relebactam have not been discussed because they are not available in India, at the time of writing this guideline.